Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) CHB or Clevudine and Peg-interferon Sequential Treatment in Patients With CHB Who Have HBeAg(+).

Next Previous
Trial Profile

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) CHB or Clevudine and Peg-interferon Sequential Treatment in Patients With CHB Who Have HBeAg(+).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clevudine (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bukwang Pharmaceutical

Most Recent Events

  • 17 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 25 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
  • 25 Dec 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top